Breaking News

Sun Pharma & Samsung BioLogics Ink Mfg. Deal

Enter $50 million strategic manufacturing tie-up for Tildrakizumab

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sun Pharma and Samsung BioLogics have formed a strategic long-term manufacturing agreement for Tildrakizumab. The agreement was entered into by Sun Pharma’s wholly-owned subsidiary and Samsung BioLogics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis. Filings for this novel investigational biologic has been accepted for review ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters